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Hematology Oncology 
The primary objective of this study is to elucidate the mechanism by which the reagent 
UCN-01 induces apoptosis when administered to leukemia cells along with HmG-CoA 
reductase inhibitors, mainly the statins. In this study, we demonstrated that exposure of 
leukemia cell lines to lovastatin (20 uM, 18 hours) and UCN-01 (1 00 nM, 18 hours) 
resulted in mitochondria1 dysfunction, procaspase 3 and 9 cleavage, and PAW degradation 
along with marked cytochrome C release and apoptosis. Although similar molecular 
mechanisms have not yet been confirmed in other cancers, our hypothesis holds that 
enhanced apoptotic effects of UCN-01 are due in part to lovastatin's ability to block 
formation of geranylgeranylpyrophosphate and farnesylpyrophosphate by interfering with 
10 
the rate-limiting step of the mevalonate pathway. Geranylgeranylpyrophosphate and 
farnesylpyrophosphate induce post-translational modifications in RAS that anchor the 
protein to the cell membrane so that it acts as a signal transducer to the nucleus, promoting 
cell proliferation. 
INTRODUCTION 
1.1 Mechanisms of Cancer Proliferation and Survival 
Hematopoietic cells originate from common stem cells, which have pluripotent 
function and give rise to two types of progenitors, B lymphocytes and T lymphocytes or 
leukocytes and erythrocytes. The process of continual hematopoietic proliferation and 
differentiation of cells is balanced physiologically through apoptotic or mechanisms that 
induce cell death. Cancers including leukemia and multiple myeloma are due in part to 
errors existing in genetic code within immature hematopoietic cells resulting in abnormal 
expression of proteins and evasion of cell death, hindering cell maturity. Most 
chemotherapies target the specific pathways that initiate inappropriate protein expression 
in cancer cells in an attempt to induce apoptosis. 
1.2 Cell Cycle 
Several transforming mutations involving RAS/RAF/MEKfERK and PI3 WAKT 
pathways have been linked to cell cycle arrest or inappropriate activation of CDKs thus it 
is important to study the underlying mechanisms that control the transition of the cell from 
one stage to the next. Cells proceed through five phases: the S, GI, G2, M, and Go. In the 
Go phase, terminally differentiated cells withdraw from the cycle. Once extracellular 
signals commit the cells to entry in the G1 phase, RNA and protein synthesis prepare the 
cell to divide, cells passing a restriction point are therefore committed to entry into the S 
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phase. The transition of the GI to S phase is tightly controlled by protein kinases that 
change their conformation in response to extracellular signals. Protein kinases 
phosphorylate specific proteins at specific times to coordinate metabolic activities and 
initiate orderly cell division, consisting of a regulatory (cyclin) and a catalytic (CDK) 
subunit. When cyclin binds, the catalytic site opens and activity of the CDK increases 
10,000 fold. There are several forms of cyclinlCDK complexes corresponding to the 
transition of each stage of the cell cycle. During the first phase of the cycle, the G1 phase, 
cyclin D forms a complex with the CDK4 or CDK 6 subunit. Once cyclin D associates 
with CDK4 or 6, phosphotase Cdc25C acts as a checkpoint control to DNA damage in the 
S phase. This CDK complex then phosphorylates the protein Rb, which is a tumor 
suppressor protein involved in sequestration of E2F transcription factors that prevent 
activation of genes critical for DNA synthesis during the S phase. Once Rb is 
phosphorylated, E2F transcription factors are expressed, allowing DNA synthesis during 
the S phase. In several studies, overexpression of cyclin D or loss of Rb function has been 
linked to tumors. Late in GI, cyclin E forms a complex with CDK2 and this marks the 
entry of the cell into the S phase. The synthesis of cyclin E promotes the synthesis of 
additional E2F transcription factors, thus, this process acts a positive feedback loop. Once 
in the S phase, cyclin E is degraded and CDK2 associates with cyclin A and B, allowing 
the cell to enter mitosis and undergo cell division. Progress through mitosis requires that 
there is timed activation and then destruction of cyclins A and B, which activate CDK2. 
Continual synthesis and degradation of cyclins allow their counterpart, CDKs to become 
activated at appropriate times, followed by inactivation. 
As illustrated in Figure 1.1, production of cyclins followed by their degradation 
allows for transitioning of the cell from one phase to the next, while CDK levels remain 
fairly constant. These CDKs are tightly controlled and depend on association with cyclins 
followed by inactivation of CDKs through action of anti-growth factors and CDK 
inhibitors belonging to either Cip/Kip family or CDK4 inhibitors. Members of the Kip 
family include p21, p27, and p57 and may inhibit CDK 2,4, and 6. 
Figure 1.1 Cyclin Synthesis and Degradation (18) 
Cyclin Expression Fluctuates 
throughout a Cell Cycle 
Mitogen Stimulation 
Figure 1.2 illustrates the corresponding cyclin-CDK complexes that regulate the 
cell cycle. In several tumors, inappropriate activation of CDKs has caused cell proliferation 
in the absence of extracellular signals such as hormones. There have been several synthetic 
inhibitors created that modulate CDK activity to induce apoptosis, causing cell cycle arrest 
in an attempt to counteract continual cell proliferation brought about by cancer. Most of 
these inhibitors act via interaction with the ATP site of cdk's, these inhibitors include 
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UCN-01, flavopiridol, and roscovitine. In this study, the major CDK inhibitor was 7- 
hydroxystaurosporine, an analog of UCN-01 . 




7-hydroxystaurosporine has been classified as a specific analogue of staurosporine 
that specifically targets protein kinases (24). UCN-01 specifically inhibits protein kinase C 
isoenzymes, specifically those isoforms that are calcium dependant. The reagent has a 
hydroxyl group at the C-7 position of the indolocarbazolo moiety with the following 
structure. 
Figure 1.3: Chemical Structure: Staurosporine (28) 
Although it is apparent in some tumors that UCN-01 acts via targeting of PKC enzymes; 
other tumors treated with UCN-0 1 indicate an alternate mechanism of action (12). One 
theory is that UCN-01 induces inhibition of CDKs at high concentrations in vitro, while S- 
G1 arrest was observed at lower concentrations. In the most recent studies on the effects of 
UCN-01 on cell cycle control, upregulation of the protein p21 was observed, which as 
mentioned previously is involved in deactivation of CDKs and subsequent cell cycle arrest. 
Since p21 has similar promoter regions to those existing in the proto-oncogene protein 
RAS, which activates p21, scientists have studied the effects of UCN-01 on other kinases 
activated by the protein RAS including MEWERK have been investigated. 
Previously, it has been found that at concentrations 2 100 nM, UCN-01 
significantly increases ERK activity and similar concentrations were found to increase 
activation of MAPK, another pathway regulated by RAS. Thus, the increased activity of 
p21 is due to increased activation of MEWERK and MAPK leading to observed cell cycle 
arrest. Although these studies aid understanding of the mechanism involved in apoptosis 
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when cells are exposed to UCN-01 alone, the apoptotic effects are minimal. In this study, 
UCN-0 1 was used at lower concentrations (1 00- 1 50 nM) in combination with other 
inhibitors. In our studies, it was discovered that UCN-01 in combination with 
famesyltransferase inhibitors (LY744), caused G2/M abrogation, while interfering with 
UCN-0 1 induced activation of the MEKERK pathway. 
1.4 Mevalonate Pathway 
In the past, statins have mainly been involved in control of cholesterol where their 
mechanism of action has been to block an essential component of the mevalonate pathway 
(1 8). Here, the rate-limiting step of the pathway is conversion of HMG-CoA to 
mevalonate, which then leads to products, which have various functions within .the cell. 
The products contain isoprene units a d  include GGPP (geranylgeranyl pyrophosphate), 
FPP (famesyl pyrophosphate), and cholesterol. Geranylgeranyl and farnesyl transferases 
use the substrates, GGPP and FPP to perform post-translational modifications to GTP- 
binding proteins so that they may function, these proteins include RAS and other proteins 
belonging to families Rho, Rac, etc. (2). For RAS to act as a signal transducer the protein 
must be localized to the cytosolic face of the membrane, which occurs by attaching 
hydrocarbon moieties to the existing protein. In this case, RAS is anchored to the 
membrane by two such moieties, either farnesyl or geranylgeranyl hydrocarbons. The bond 
between the famesyl or geranylgeranyl group and RAS protein is a thioester linkage, 
which is formed with the cysteine group close to the carboxyl terminus of the protein and 
the hydrogen on the farnesyl or geranylgeranyl moiety. Following modification of RAS, 
the protein undergoes proteolysis in which three of the terminal residues of the protein are 
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removed and the carboxy terminus is methylated. The transfer of the farnesyl moiety 
required for the above reaction is catalyzed by the enzyme famesyltransferase, which 
interacts with the substrates produced by the mevalonate pathway, FPP 
(famesylpyrophosphate) and GGPP (geranylgeranylpyrophosphate). As previously 
reported inhibition of farnesyltransferase inhibits localization of the RAS protein to the cell 
membrane, and subsequent activation of downstream signaling pathways. The lethality of 
farnesyl transferase inhibitors were enhanced when combined with UCN-0 1. However, 
RAS isoforms may still overcome the effects of these inhibitors since geranylgeranyl 
moieties also bind particular members of the RAS family, including HRAS and NRAS to 
the cell membrane. As mentioned above, blocking RAS may dramatically enhance the 
effects of the CDK inhibitor, UCN-01 (4). One of the theoretical advantages of using 
HMG- CoA reductase inhibitors is the tolerance exhibited by patients of side-effects and 
decreases in the amount of FPP and GGPP produced, which are required for 
farnesyltransferase to function and to modify RAS. Generally, there are four different 
forms of statins. Fluvastatin and atorvastatin are synthetically derived whereas simvastatin 
and lovastatin are fungal derivatives (2). In this study, we are primarily concerned with 
three forms of the drug: Lovastatin, simvastatin, and fluvastatin and their actions when 
combined with UCN-0 1. 
The RASRAFIMEWERK pathway is often referred to the MAP kinase pathway or 
mitogen-activated protein kinase. The pathway is stimulated by a variety of factors 
including activation of growth factors, cytokines, and mitogens responsible for cell 
division and induction of mitosis initiated by factors in the extracellular medium. In 
cancer, the MEWERK pathway is activated by RAS in the absence of growth factors or 
hormones, RAS subsequently promotes the translocation of RAF-1 from the cytosol to the 
cell membrane, and RAF is then activated by phosphorylatioii and dephosphorylation. 
RAS is a small GTP-binding protein that is activated by binding to GTPase activating 
proteins and guanine nucleotide exchange factors. RAS will cycle between the active form, 
which is bound to GTP and the inactive state, bound to GDP for short periods of time. In 
cancers, RAS bound to GTP is hydrolyzed in its active state for an abnormally long period 
of time accumulating growth-promoting signals sent to the nucleus in the absence of 
growth factors or hormones, in turn, activating the MAPKinase cascade described later in 
this section. There are several family members of RAS protein including HRAS, KRAS, 
and NRAS. The major isoforrns found in almost 30 percent of cancers include KRAS and 
NRAS. RAS not only activates RAF-1 and the MEWERK kinases, it is the major regulator 
of the survival pathway, PI3WAKT. 
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1.6 P13KfAKT Pathway 
The PI3WAKT survival pathway is one of several pathways involved in cell cycle 
regulation as mentioned previously. Specifically, PI3WAKT is responsible for 
phosphorylation of T145 and S146 near the carboxyl terminus of p21 leading to activation 
of CDK and DNA synthesis and an increase in cell proliferation (3). 
The PI3WAKT pathway is activated via cytokine activity for specific receptors that 
activate PI3 Kinase. The exact mechanism, by which PI3WAKT is activated, occurs when 
PI3K is recruited to the plasma membrane and is phosphorylated at Thr308 by PDKl and 
at Ser473 by PDK2. PP2A is a serinelthreonine-specific phosphatase that has been shown 
to inhibit PI3WAKT kinase activity. Thus, PDKlPDK2-mediated phosphorylation at both 
sites and PP2A-mediated dephosphorylation must work in conjunction to mediate the 
PI3WAKT kinase activity in vivo (3). PI3WAKT then mediates several cellular responses 
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such as glucose uptake and several downstream anti-apoptotic proteins including those 
involved in the mitochondria1 pathway such as Bcl-xl and Bcl-2. The following Figure 
illustrates several mechanisms of survival for the PI3IUAKT pathway. 
Figure 1.5 Multiple Mechanisms of Cell Survival Regulation by PI3K/AKT/PKB (3) 
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Another mechanism by which PI3KIAKT suppresses apoptosis is through 
inhibition of apoptotic proteins belonging to the caspase family of cytosolic proteases (5). 
Reports indicate that suppressing the PI3IUAKT pathway with PI3 Kinase inhibitors such 
as LY294002 (farnesyltransferase inhibitors) synergistically enhances the cytotoxic effects 
of anticancer drugs such as UCN-01. 
1.7 Crosstalk Between RAS/RAF/MEK/ERK and PI3WAKT 
Although RAS regulates several pathways including PUIUAKT, ERK 112, and the 
Ral GDS pathways, recently it has been found that crosstalk between PI3WAKT and RAF 
may occur since PI3KlAKT can directly phosphorylate RAF isoforms, however these 
effects depend on the cell type and differentiation process. The first indication of possible 
crosstalk between the pathways was evident when inhibition of PI3WAKT was shown to 
cause a marked decrease in the amount of expression of p-ERK. In previous studies it has 
been demonstrated that farnesyltransferase inhibitors such as LY294002 that inhibit 
PI3WAKT also induce expression of B-RAF. Such findings warrant further study as to the 
exact interaction between the PI3WAKT and RAF pathway. 
Figure 1.6 PI3KlAKT Pathway and Downstream Targets of RAS 
(anti-apoptotic) 
RAS RALGDS ' 
1.8 Cell Death 
Although there are several pathways which promote cell survival, these 
mechanisms must be balanced physiologically through apoptosis or cell death. Cell death 
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cell death in living organism with failure of membrane integrity. The cell membrane and 
membranous structures within the cell become permeable as opposed to their normal 
physiological state. A number of toxic chemicals or physical events can cause necrosis 
including toxins, radiation, heat, trauma, or lack of oxygen. This process follows cell 
injury and the resulting dead cells induce an inflammatory response. Necrosis is 
distinguished from apoptosis in that apoptotic cell death results from energy dependent, 
metabolically active, endogenous cellular processes where membrane integrity is 
maintained. 
The induction of apoptosis generally follows one of the two related biochemical 
pathways, either extrinsic or intrinsic. The extrinsic pathway is initiated by the cell-surface 
molecules belonging to the tumor necrosis factor (TNF) family of receptors (Fas[DR2], 
DcR3) and their respective ligands. 
Typically, receptors belonging to the TNF form what is known as a death-inducing 
signal complex or DISC when paired with their respective ligands. Directly following 
formation of the complex, caspase 8 and caspase 10 proteins are activated, which activate 
effector proteins caspase 3 , 6 ,  and 7 downstream. Caspases are cytosolic proteases that 
participate in apoptosis when there is a signal from .the receptor. All caspases are 
synthesized as inactive proenzymes and all have a critical cys residue at the active site. 
The Fas receptor, a member of the TNF fanlily, induces apoptosis via a mechanism 
similar to that mentioned above. Apoptotic response is initiated when binding of a cluster 
of Fas receptors at the plasma membrane results in the recruitment of cytosolic protein, 
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FADD and formation of the pro-caspase 8 complex. High concentrations of the cytosolic 
proteasome, pro-caspase 8 results in its autocatalysis or self-activation; activated caspase 8 
cleaves effector, pro-caspase 3, which then undergoes autocatalysis to form active caspase 
3, a principle effector caspase of apoptosis. 
One area of interest in cancer research has been the TNF-related apoptosis-induced 
ligand (TRAIL) and its receptor, which has shown great promise as an anticancer reagent. 
TRAIL derivatives have been shown to induce apoptosis in tumor cells, while rarely 
inducing apoptotic responses in non-transformed cells. However, the exact molecular 
mechanism is not well understood. In contrast to Fas, TRAIL expression has been found in 
numerous tissues including the spleen, thymus, and ovary, but is absent in the brain (20). 
There are structural similarities between TRAIL and other TNF receptors; both are type I1 
transmembrane proteins expressed on the cell surface. Studies indicate that TNF receptors 
contain a specific group of molecules on the receptor that are responsible for inducing 
apoptosis; these four molecules include TNFR1, CD95, DR3, and CAR1. Each of these 
molecules contain a "death domain", an 80 amino acid cytoplasmic motif, which form a 
complex with the "death domain" on the ligand to activate the caspase cascade and induce 
apoptosis. However, experimentation indicates that receptors lacking this domain still 
retain the ability to mediate apoptosis in T-cells, indicating a more complex mechanism 
which warrants further molecular studies to elucidate the exact mechanism. 
The other major signaling pathway is the intrinsic pathway also known as the 
mitochondrial pathway and is activated via mitochondrial membrane damage and may be 
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triggered from within the cell as opposed to the ligand-receptor system involved in the 
extrinsic pathway. Apoptosis through this mechanism is detected through release of a 
carrier protein, cytochrome C, from damaged mitochondria that binds a protein, Apafl. 
This cascade of events initiates caspase 9 that activates effector caspase 3. A delicate 
balance exists in which apoptotic proteins such as SMACIDIABLO and OmilHtrA2, which 
are released from the mitochondria, may inhibit the action of anti-apoptotic proteins such 
as Bcl-2 and XIAP. The common protein that links the extrinsic and intrinsic pathways is 
caspase 3 whereas several anti-apoptotic proteins such as XIAP target effector caspase 3 
and 7, preventing apoptosis. 
In summary, several major pathways exist that promote cell survival including 
PI3WAKT and MEWERK, both of which are activated by the protein RAS. These 
pathways are complex and influence cell cycle activity. In addition, these survival 
pathways influence apoptotic responses brought about by the caspase cascade, which may 
be triggered within the cell or via the extrinsic pathway. In this study, the PKC and Chkl 
inhibitor UCN-0 1 was administered at low concentrations (1 00- 150 nM) in conjunction 
with HMG-CoA reductase inhibitors in an attempt to induce dramatic apoptosis in 
leukemia cells lines and define the exact molecular mechanism involved in this response. 
Materials and Methods 
2.1 Cell CultureMaintenance 
Human Cell Lines: 8226/Sensitive, lR  M.M., U266, U937, and Jurkat are multiple 
myeloma-sensitive, multiple myeloma, histiocytic lymphoma, acute promyelocytic 
leukemia, and acute T-cell lines, respectively obtained from American Type Culture 
Collection (Rockville, MD). Cells were maintained in 1640 RPMI Gibco medium 
containing 2mM C5HI0N2O3 (L-glutamine), 2 grams NaHC03, 10 ug/ml of penicillin, 1 
mM C3H3Na03, 100 UM MEM nonessential amino acids, and 100 ug/n-11 streptomycin 
supplied by Gibco in powder form and dissolved in 1 liter ultrapure water. The pH of the 
resulting medium was adjusted to 7.25 using NaOH or HC1 according to readings from an 
Omega pH meter. The medium was sterilized using vacuum filtration through a 0.22 p 
filter unit from Pall (Bridgeport, NJ). The bottles of medium were stored at 4OC. Prior to 
use medium was supplemented with 50 ml of FBS (fetal bovine serum). Cells were 
incubated in a Greiner T-25 cm2 flask from ISC Bioexpress in a humidified incubator at 
37°C and 5% C02. Once cells were obtained from American Culture Collection, the vial of 
cells was thawed and cultured (free-floating) in approximately 10 ml of medium for 
approximately 2-3 days. Once the cells reached a density of approximately 3 - 5 x 1 o5 
cells/ml, a volume of 0.5 ml cells were taken from the T-25 cm2 flask and placed in 10-12, 
1 ml cryovials containing 0.5 ml Cryo solution (Sigma-Aldrich), were frozen and stored in 
a liquid nitrogen tank. Cells stored in the nitrogen cryogenic storage vessel were used as 
needed for experimentation. One cryovial containing cells was thawed and washed 2-3 
times in 1 ml of Gibco medium to remove DMSO (see above for contents). Cells 
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resuspended in 1 ml of medium were added to a T-25 cm2 flask already containing 
approximately 10 ml of Gibco medium. Cells were incubated starting from passage 
number 3 to 60, in a humidified incubator at 37OC and 5% C02. For these cell lines no 
additional drugs or reagents were added when maintaining cell culture. 
2.2 Determination of Cell Density 
In order to maintain the cell density between 3 - 5 x 10' cells/ml, a coulter 22  
particle counter from Beckman Coulter (Fullerton, CA) was used to determine the density 
of cells in 1 ml of fluid. The coulter counts the amount of particles passing through the 
aperture based on the particle size, which is 6 um to 8 um for cells. Smaller cell sizes 
indicate shrinkage, fragmentation and corresponding cell death. To determine the cell 
density, a 500 uL vol~une of each cell line maintained was obtained from the flask of 
growing cells and diluted in 1 ml of conductive fluid obtained from Beckman Coulter. The 
dilution was thoroughly mixed and then passed through a cylindrical aperture on the 
coulter 22 particle counter from Beckrnan Coulter (Fullerton, CA) that modulates 
inipedance of two electrodes positioned on either side of the apparatus every time a particle 
passes through the aperture. As each particle passes through the aperture, the circuit is 
interrupted and an electrical pulse is sent through the circuit, in this case the particles 
passing through the aperture are cells. The number of electrical pulses corresponds to the 
number of cells and this number is then illustrated as a peaked curve on a liquid crystal 
display along with a numerical value on the bottom of the display. This value indicates to 
the user the number of cells in 1 ml of conductive fluid or concentration of cells. In this 
case, the range of particle sizes may be specified by the user so that the window displays 
particles that range in size from 6um to 8 um, which are the typical sizes for living 
myeloma and leukemia cell lines. To assess cell viability or for a more precise indication 
of cell viability trypan blue analysis is used in cases where inconsistent cell growth is 
indicated or there is discoloration of the medium during cell culture. 
2.3 Cell Viability 
Trypan blue is one method by which cell viability may be evaluated using a system 
of scoring of four separate fields on a prepared hemocytometer (Sigma -Aldrich). First 100 
uL of cells were taken from the T-25 cm2 flask and placed in a 0.5 ml microfuge tubes. 
Then 100 uL of 0.4% trypan blue solution (Sigma-Aldrich) was resuspended in the 
microfuge tube. The suspension of cells and trypan blue stain was then injected into the 
hemocytometer (Sigma Aldrich). Cells in all four fields were counted and the number of 
cells that lacked stain was determined accordingly. Living cells would lack stain since their 
membranes are in tact, whereas cells with blue stain are damaged due to incorporation of 
the stain into the cell because of membrane damage. 
2.4 DNA Amplification and Purification 
DNA purification is used so that DNA may efficiently be transfected in eukaryotic 
cells. DNA HRas plasmid was ordered from Upstate Biotechnologies and propagated in a 
DH1 e-coli host strain. The bacterial colonies were grown in a 1.5 % prepared agar plate 
(agar fkom Invitrogen) with 50 ug/ml of ampicillan. Once bacterial colonies were visible, a 
single colony was picked fkom the prepared agar plate and inoculated in 2-1 0 ml of Luria 
Bertani (LB) medium from Qiagen (1 L contains 10 grams NaC1, 10 grams tryptone, 5 
grams yeast, and 800 ml ultrapure water). The final pH of the medium was adjusted to 7.0 
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by adding NaOH, and HC1. The inoculated bacterial culture was incubated for 
approximately 8 hours at 37OC and shaken at 3000 rpm in a Lab-Line incubator/shaker. 
The starter culture was further diluted in 500 ml of selective LB medium for every 1 ml of 
the starter culture. The above procedure was repeated this time for 12 - 16 hours, the 
bacterial cells in LB medium were then harvested by centrifugation at 6000 x g at 4OC 
using a Jouan, Model CT 4 22 centrifuge for approximately fifteen minutes and the 
suspension was aspirated to obtain a pellet of bacterial cells. Purification of the resulting 
pellet was performed using an Endotoxin Free kit from Qiagen. The bacterial pellet was 
isolated and then resuspended in 10 ml of P1 Buffer. 1L of P1 contains 6.06 grams of Tris 
base obtained from BioRad Companies, 3.72 grams Na2EDTA, and 100 mg RNase in 
ultrapure water. The P1 buffer pH was adjusted to 8.0 using NaOH and HC1. Then 10 ml 
of P2 buffer was added to the suspension and the resulting mixture was incubated at room 
temperature for five minutes. 1 liter of P2 buffer contains 8 grams NaOH, 50 ml of 20% 
SDS, and ultrapure water to a final volume of 1 liter. The resulting lysate was viscous and 
contained contaminants; these impurities were removed via filtration through a qiagen 
filter cartridge as instructed by the Qiagen supplier. The resulting eluate was collected in 
pyrogen-free tubes provided by Qiagen. DNA was then precipitated using 10.5 ml of 
isopropanol warmed to room temperature. The suspension was then mixed and centrifuged 
at 15000 x g for approximately 30 minutes at 4OC (Jouan, Model CT 4 22) in a 50 ml 
conical tube. The supernatant was removed and the resulting pellet was resuspended in 5 
ml of ethanol. The resulting suspension was centrifuged again at 15000 x g for 
approximately 10 minutes at 4OC, the suspension was aspirated and the resulting pellet was 
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dried in air at room temperature. The pellet was then resuspended in 10 uL endotoxin 
buffer-TE provided by Qiagen. 1 liter of TE buffer contains 5.84 grams NaC1, 1.21 grams 
Tris base, and 0.37 grams Na2EDTA in ultrapure water to a final volume of 1 liter and pH 
of 8.0. 
2.5 Transfection of DNA into U266 Cells 
In order to transfect the purified DNA, first U266 cell lines were adjusted to a 
density of 3-5 x lo5 cells per ml and the density was confirmed using the coulter 22 
particle counter from BeckmanCoulter (Fullerton, CA). Then 1 ug of DNA obtained from 
the procedure in section 2.4 was prepared in 5 uL of ultrapure water. A 12 well plate from 
Nunclon Surface Technologies was then filled with 1.5 ml of 1640 RPMI medium to each 
well (see section 2.1 for contents). Next, U266 cells were centrifuged in a 50 ml conical 
tube at 90 x g for 10 min in a Jouan, Model CT 4 22 centrifuge. The supernatant was 
discarded and the resulting pellet of U266 cells were resuspended in Cell Line 
Nucleofactor solution warmed to room temperature for approximately 20 minutes (Amaxa 
Biosystems, Koln, Germany). Then the 1 ug of DNA in ultrapure water was added to the 
prepared suspension of U266 cells in nucleofactor solution. Then 500 uL of suspension 
consisting of cells and DNA was transferred to an amaxa cuvette and the sample was 
placed into a Nucleofactor I system from Amaxa Biosystems (Koln, Germany). In this 
case, we used nucleofactor technology; program V-01, which was preset by Amaxa 
Biosystems. Once transfection of U266 cells was complete, 500 uL of pre-warmed 1640 
RPMI culture medium was added to the cuvette and 500 uL of U266 cells in medium with 
the new DNA was transferred to each well in the prepared plate. The 12 well plate was 
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incubated in a humidified incubator at a temperature of 37"C/ 5% C02  for approximately 
24 hours to ensure peak expression of the HRas gene. Expression of the gene was 
confirmed using western blot analysis described in the later sections. 
2.6 Reagents 
UCN-0 1 was obtained from .the National Cancer Institute from Dr. Edward 
Sausville. UCN-01 was dissolved in sterile DMSO and frozen under light-protective 
conditions at -20°C (5). Lovastatin, Simvastatin, and Fluvastatin were purchased from 
Calbiochem (San Diego, CA). The lovastatin, simvastatin, and fluvastatin were dissolved 
in DMSO solution and stored at -80 OC in light-protective 1 ml microfuge tubes. Prior to 
use appropriate dilutions were made for all experiments with sterile DMSO. 
2.7 Experimental Format 
Experiments were conducted using sterile 6 or 12 well plates obtained from 
N~mclon Surface. For each experiment a volume of 1000 uL of logarithmically growing 
cells at a density of approximately 3-5 x 10' cells/ml were added to each well. Cells were 
then treated with UCN-0 1, Coenzyme reductase inhibitors (Calbiochem San Diego, CA) or 
a combination of these and incubated at a temperature of 37 "C/ 5% C02  at various time 
intervals, generally intervals of 18 or 36 hours. After treatment, cells were subjected to 
analysis to determine the extent of apoptosis using the following techniques. 
2.8 Analysis of Apoptosis 
The extent of apoptosis was first determined by viewing slides prepared by 
cytospin in a Cyto-Tek centrifuge made by Sakura Finetek for 10 minutes at a speed of 5 
rpm. The slides were encased in a filter cartridge with filters obtained from Cyto-Tek. 
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Approximately 3000 uL of cells were used in each cartridge. Once centrifuged, the slides 
were stained with Wright-Giemsa stain preparation (Sigma-Aldrich) and viewed under 
light microscopy using a Zeiss Axiovert 40 x CFL microscope. "Scoring" was performed 
by approximation of the number of cells that exhibited classical morphological features of 
apoptosis including condensed nuclei and membrane damage (5). For each condition, 4 or 
5 randomly selected fields were evaluated, containing at least 500 cells (5). To confirm the 
results of morphological analysis, in some cases cells were also evaluated by 
oligonucleosomal DNA fragmentation of total DNA as described later in this section. 
2.9 Analysis of Mitochondrial Membrane Potential (AYm) 
Mitochondrial membrane potential is used to characterize cellular apoptosis and 
also cellular metabolism. The theory behind this assay is based on the electron transport 
chain and changes in membrane potential. The electron transport system across the inner 
mitochondria1 membrane creates a potential that is greatly reduced when the membrane is 
damaged as it would occur if the cell was undergoing apoptosis. DiOC6 (3,3- 
dihexyloxacarbocyanine iodide) is a cationic fluorescent dye. When there is accumulation 
of DiOC6, it is an indication of living cells, whereas cells that do not take up the dye are 
dead cells. In this procedure a volume of 300 to 4.00 uL of cells are transferred to a Falcon 
brand polystyrene test tubes (12 x 75 mm). For every 100 uL of cells, 4 uL of DiOC6 
prepared stock is added to each sample of cells. The prepared stock consists of 40 uL of 
DiOC6 in 10 ml of PBS (Molecular Probes Inc., Eugene, OR). Once cells were treated 
with DiOC6 dye, cells were incubated at 37OC/5% COz for 15 min and then analyzed by 
flow cytometry using a Becton Dickinson FACScan and Cell Quest Pro Software version 
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4.1 (Becton Dickinson, San Jose, CA). FacScan channels F1-1 and F1-2 that detect levels of 
DiOC6 dye were adjusted to a range between 400 - 500 mV for F1-1 and 3 17 mV for F1-2 
depending on the cell line used in each experiment. The percentage of cells that exhibit low 
levels of DiOC6 uptake reflects loss of mitochondria1 membrane potential and apoptosis. 
2.10 Annexin V-FITC Analysis 
In this assay, once apoptotic responses are confirmed using DiOC6, annexin V 
analysis allows one to distinguish between early and late apoptosis. The early stage of 
apoptosis is detected when the membrane phospholipid phosphatidylserine (PS) is 
translocated from the inner leaflet of the plasma membrane to the outer leaflet and exposes 
PS to the external environment. Annexin V is a calcium dependant phospho-lipid binding 
protein and has a high affinity for PS. As described in the protocol, certain calcium and salt 
concentrations are required to allow binding of annexin. In order to identify cells bound to 
annexin, a fluorescent stain is used, specifically, fluorescein isothiocyanite (green 
fluorescence). Each sample of cells is harvested at a density of 1x106, and transferred from 
6 or 9 well plates (Nunclon Surface) to 1.5 ml microfuge tubes (ISC Bioexpress) and 
centrifuged using a Labnet z cytospin (Herrnle) for five minutes at 15 rpm, and then 
aspirated. The pellet of cells was washed with PBS (solution must be adjusted to a pH of 
7.2 and autoclaved). 1 L of PBS contains 1.44 grams of Na2HP04*7H20, 8 grams of NaC1, 
0.24 grams of KH2P04, and 0.2 grams of KC1. Washes in PBS were repeated two or three 
times, repeating the same procedure. PBS is then removed and the cell pellet was 
resuspended in 500 ul of the annexin binding buffer (500 ml of binding buffer contains 10 
mM of Hepes/NaOH that has a pH of 7.4, 140 mM of NaC1, and 2.5 mM CaC12). Finally, 
33 
100 uL of the cells in binding buffer were transferred to 5 ml Falcon snap cap, polystyrene 
tubes. 
This was followed by the addition of 5 uL of annexin V-FITC (BD Biosciences) to 
the Falcon tube along with 10 uL of propidium iodide stock (Sigma Aldrich). 20 ml of 
propidium iodide stock for annexin V analysis contains 50 ug of propidium iodide in 20 ml 
of l x  PBS. The Falcon polystyrene tubes were incubated in a 37"C/5% C02 incubator in 
the dark for approximately 15 minutes. The final volume of samples in the polystyrene 
tubes was adjusted to 500 uL by adding 400 uL of annexin binding buffer to the incubated 
polystyrene tubes. For annexin V analysis, Facscan from Becton Dickinson was used along 
with Cell Quest software version 4.1 x. The channels that were adjusted and correspond to 
green and red fluorescence F1-1 and ~ 1 - 3  were adjusted to 217-300 mV and 350-400 mV, 
respectively. F1-3 corresponds to propidium iodid stained cells; whereas, Annexin V stain 
corresponds to F1- 1. 
2.11 Cell Cycle Analysis 
Changes in cell cycle may provide further insight into the mechanism involved in 
apoptosis when cells are exposed to different reagents and can be measured either directly 
or indirectly. In most of the direct assays, the time course for changes in DNA and 
synthesis of DNA is measured. One direct method of identifying cell proliferation is 
through incorporation of propidium iodide (Sigma Aldrich), a standard cytometric 
fluorescence used to measure DNA content over a time course. Propidium Iodide was used 
in annexin analysis above; however, in this case other ingredients were added to form 
propidium iodide solution for cell cycle analysis. For each condition subjected to cell cycle 
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analysis, 500 uL of cells (cell density 5 - 5.3 x 1 05/ml) were treated for approximately 8 
hours with desired reagents (UCN-0 I, lovastatin, fluvastatin, and simvastatin either alone 
or in combination). The cells were then pelleted at 1500 rpm, 4" C using the Jouan, Model 
CT 4 22 and resuspended in 1.5 ml PBS followed by addition of 3 ml of 67% ethanol and 
incubated at 4OC for an hour. After centrifugation, the samples were aspirated and the 
pellet was resuspended in 1.0 ml propidium iodide solution (20 ml of propidiurn iodide or 
propidium iodide solution contained 3.8 x 10" Na citrate to neutralize the acid, 0.5 mgln-11 
RNAse, and 0.0 1 propidium iodide). 
The resulting sample was analyzed by flow cytometry using the Becton Dickinson 
Facscan and Cell Quest software as previously mentioned. The plot of F1-3 (channel 
detecting red fluorescence) was set to approximately 217 - 300 mV. Cells stained with red 
fluorescence indicate increase in DNA synthesis or changes in DNA compared to untreated 
cells. For graphing the cell cycle data obtained from Cell Quest, curves were adjusted 
manually using Modfit LT 2.0 software (Verity). In this analysis, data files were converted 
to graphs showing peaks corresponding to S, G2/M, and GI phases of the cell cycle. 
2.12 DNA Fragmentation 
One major indication of apoptosis is the cleavage of chromosomal DNA at the 
nucleosomal sites and is marked by fragmentation that occur at weights approximately 200 
base pairs. Annexin V analysis, morphological analysis, and DNA fragmentation correlate 
in showing apoptosis (5). For this assay cells were at a density of 20 x 1 o5 cells/ml for each 
sample, the cell density was confirmed using the coulter 22 particle analyzer. In this case, 
a marker that marks every 100 bp is used (Invitrogen 10748-01 0). The cell samples were 
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centrifuged at 1500 rpm for 10 minutes at 4" C (Jouan, Model CT 4 22) and the pellet was 
resuspended in Gibco medium (see section 2.1 for contents). Then 450 uL of the lysis 
buffer was added to the suspension (2 ml of lysis buffer consists of: 5 mM Tris-base from 
BioRad, 20mM EDTA, 0.5 % TritonX-100 (with a pH of 8), and 100 uglml Proteinase K). 
The lml solution containing cells and lysis buffer were vortexed and transferred to 1.5 ml 
microfuge tubes (ISC Bioexpress USA). The samples were incubated in a water bath at 56" 
C for approximately 18 hours. The samples were then centrifuged in an F-20 microrotor 
(50,000 x g) for 45 minutes. This action separated the larger particles of the cell from the 
cellular species of lower weight. The supernatant was carefully removed without touching 
the pelleted cells at the bottom of the microfuge tube and the solution was transferred to a 
new 1.5 microfuge tube. RNase A (Sigma-Aldrich) was then added to the existing solution 
at a concentration of 200 ug RNase per 1 ml of lysis bufferlcells. 
These samples were incubated for 3 hours at 37"C/5% C02. The 1.8% agarose gel 
obtained from Gibco-BRL was mixed with a 500 ml volume of TBE buffer (1L of TBE 
buffer contains 54 grams Tris-base, 27.5 grams boric acid, 20 ml0.5M EDTA (pH = 8.0) 
in 1 liter of milli Q water). The prepared agarose was poured into a BioRad apparatus and 
allowed to set to form a gel before electrophoresis using a 2 rnm tooth comb (BioRad) was 
conducted. The gel was subjected to 120 volts until the purple band (DNA marker from 
Invitrogen) migrated to a position 3-4 inches from the bottom of the BioRad apparatus. 
2.13 Clonegenicity 
To evaluate colony-forming ability following drug treatment, a soft agar cloning 
assay was performed. Cells were briefly washed approximately three times with serum-free 
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1640 RPMI medium (Gibco Life Technologies, see section 2.1 for contents). 
Approximately 5000-50,000 cells/condition were used and the density was adjusted using 
the Becton Dickinson Coulter 22  particle size analyzer. Then a 1 % agar solution in 
ultrapure water was prepared (agar fiom Invitrogen). A heat block from Fisher Scientific 
was used to keep the agar warm (heated to 45OC) and prepared agar solution was aliquoted 
to five 15 ml conical tubes. RPMI medium (Gibco Life Technologies) containing 20% 
FBS was then added to five more separate conical tubes. Drug treatments were washed 
from the treated cells using 1640 RPMI medium with 10% FBS (contents as described in 
section 2.1). The coulter counterlparticle size analyzer to determine cell density and the 
density was adjusted to 5000 - 50000 cells/ml according to the Becton Dickinson 22 
Coulter counter. 1 ml of solution consisting of medium, agar and cells were added to a 12- 
well plate (three wells per condition) with each well containing the same cell density. The 
plates (Nunclon Surface Technologies) were placed in a 37"C/5% C02, fully humidified 
incubator. Within the culture plates, 1 ml of ultrapure water was added between the wells 
to ensure that the agar remained flexible. After 10 days of incubation visible colonies of 
cells in agarose gel were scored using an Olympus Model CK inverted microscope (Model 
AX70) and colony formation for each condition was calculated in relation to values 
obtained for control cells (5). 
2.14 Western Blot Analysis 
Western blot analysis is generally used to view proteins according to weight. 
Approximately 10 - 15 ml of heated cells at a density of 5-7 x 10' cells/ml were 
transferred to a 15 ml conical tube and pelleted using a Jouan, Model CT 4 22 centrifbge at 
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12,800 x g for five minutes at 4OC, the supernatant was removedldiscarded and the 
remaining pellet was lysed by sonication (Misonix Model 2, Inc) in l x  sample buffer (2 ml 
of 1 x sample buffer is composed of the following: 62.5 mM Tris base (pH 6.8), 2% SDS, 
50 rnM dithiothreitol, 10% glycerol, 0.1 % bromphenol blue, and 5 mglml each 
chymostatin, leupeptin, aprotinin, pepstatin, and soybean trypsin inhibitor (CLAPS), 1 mM 
each sodium vanadate, sodium pyrophosphate (Na PPi)). Following sonication, the cells 
lysated in sample buffer were transferred from the 15 ml tube conical tube to the 1.5 ml 
micrifuge tubes and boiled for 5 min. The microfuge tubes containing the cells and sample 
buffer were centrifuged at 12,800 for 5 min in a Hermle z cytospin from Z Net. Once 
centrifuged, the cell samples were transferred to another 1.5 ml microfuge tube. Protein 
concentration for each cell sample was quantified using Coomassie Protein Assay Reagent 
(Pierce, Rockford, IL) (4). In this case, a Hitachi U-2000 spectrophotometer was used at a 
wavelength of 595 nm in order to assure equal loading of protein during electrophoresis. 
For measurements taken, 1 ml of ultrapure water was distributed to cuvettes along 
with 1 ml of coomasie reagent, and 1 uL of sample. The absorbance exhibited by each 
sample was then measured using the Hitachi spectrophotometer. One cuvette containing 
only coomassie reagent and water was used for calibration of the instrument. Each sample 
was gently inverted to mix the sample and measurements were automatically recorded in 
uglul. Appropriate calculations were performed to ensure equal loading of cell samples 
into the BioRad pre-made SDS gels with a 4-1 5% Tris-HC1 gradient and 15 uL volume 
wells (catalog number 161-1 158). The pre-made gels were place into a BioRad apparatus 
and enough n m i n g  buffer was added to cover the bottom half of the apparatus (2L of 5 x 
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Running Buffer stock consisted of 188 grams of glycine, 30.4 grams of tris base, and 10 
grams of SDS, and adjusted to a pH of 7.6. For making 2 L of running buffer, 400 ml of 
stock was used and milli Q water was added to adjust the buffer volume to 2L). Finally, 
samples were separated by SDS-Page electrophoresis at a voltage of 120 mV for 
approximately for an hour and a half or until the straight purple band or marker (Invitrogen 
10748-010) has reached approximately 3 inches from the bottom of the apparatus. The gel 
samples were then transferred onto a 0.2 y nitrocellulose membrane (BioRad). For 
transferring protein from the gel to a nitrocellulose membrane, cassettes (Fisher Scientific) 
were soaked in transfer buffer (6 L transfer buffer contains 348 grams of glycine, 30.4 
grams of tris base, and 3200 mL of methanol, and milli Q water filled to a volume of 6 L , 
and adjusted to a pH of 7.4). The sponge pad in the cassette was covered with filter squares 
(Whatman 3M filter paper) before the gel was added on top of the filter. The combs and 
bottom edge of the gel were removed before placing it on the filter and covering the gel 
with the square nitrocellulose membrane. Rollers from Fisher Scientific were used to 
remove air bubbles fiom the gap in between the gel and membrane. The cassette was 
placed into the BioRad transfer box already containing transfer buffer. Once four cassettes 
were added to the BioRad transfer box, transfer buffer was added to fill the box. The 
transfer box was then set to receive 400 mA for two hours. 
After transfer, cassettes were removed, the gel and filter discarded, and 
nitrocellulose membranes were blocked with 5% milk (Carnation) in TBS-Tween 20. 2L of 
10 x TBS-Tween 20 stock consisted of 24.2 grams Tris base, 80 grams NaC1, and 1 liter of 
milli Q water. From stock to make a 2L solution of 1 x TBS-Tween 20 200 ml of the stock 
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was used along with 2 ml of tween-20 and approximately 1.8 liters of ultrupure water to 
achieve a final volume of 2 liters. The membranes were kept in the blocking solution at 
room temperature for 1 hour. Then the blocking buffer was removed and the membrane 
was probed with the desired primary antibody (see below for the specific primary 
antibodies used). Before each primary antibody could be added to the membrane 
appropriate dilutions of primary antibody were made in 5% BSA with 1 x TBS-Tween 20 
(see above for TBS-Tween 20 contents). The membrane was incubated on a Lab-Line 
shaker in the desired primary antibody/5% BSA in TBS-Tween 20 overnight at 4°C. The 
blots were then washed twice in TBS-Tween 20 for 15 minutes and then incubated with a 
1 :2000 dilution of horseradish peroxidase-conjugated secondary antibody (anti-mouse or 
rabbit) (Kirkegaard & Peny, Gaithersburg, MD) in 5% milk1TBS-Tween 20 at room 
temperature for 1 hour. After washing twice in TBS-Tween 20 for 15 min, the proteins 
were visualized via Western Blot Chemilurninescence Reagent (Perkinson and Elmer Life 
Science Products, Boston, MA) (4). Finally, to ensure equal loading and transfer of 
proteins, the blots were reprobed with antibodies against actin (Signal Transduction 
Laboratories) or tubulin (Calbiochem). 
The following antibodies were used as primary antibodies: phospho-p38 MAPK 
(Thr180/Tyr182) antibody (1 : 1000; rabbit polyclonal; NEB); phospho-JNK 
(Thr183/Tyr185), JNK1, JNK2, phospho-Akt (Ser473), Akt; Cell Signaling Technology); 
phospho-cdc2 (Tyrl5) antibody (1 : 1000; rabbit polyclonal; Cell Signaling Technology); 
anti-p2 1 CipIWAF 1 (1 500; mouse monoclonal; Transduction Laboratories, 
Lexington,KY); anti-p27kipl (1 500; mouse monoclonal; PharMingen, San Diego, CA); 
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antihuman Bcl-2 oncoprotein (1 :2000; mouse monoclonal; DAKO, Carpinteria, CA); Bax 
(N-20; 1 :2000; rabbit polyclonal; Santa Cruz Biotechnology Inc.); Bcl-xS/L (S-18; 1 :500; 
5 107 rabbit polyclonal; Santa Cruz Biotechnology Inc.). Antihuman/mouse XIAP (1 :500; 
rabbit polyclonal; R&D System, Minneapolis, MN); anti-Caspase-3 (1 : 1000; rabbit 
polyclonal; PharMingen); cleaved-Caspase-3 (Mr 17,000) antibody (1 : 1000; rabbit 
polyclonal; Cell Signaling Technology); anti-Caspase-9 (1 : 1000; rabbit polyclonal; 
PharMingen); anti-PARP (1 :2500; mouse monoclonal; Calbiochem); and cleaved PARP 
(Mr 89,000) antibody (1 : 1000; rabbit polyclonal; Cell Signaling Technology). 
2.15 Analysis of Cytosolic Cytochrome C 
Cells (2 -3 x1 o6 cells/ml) were centrifuged and washed in PBS then lysed by 
incubating for 30 seconds in 2 mL of lysis buffer. The 2 ml of lysis buffer contains 75 mM 
NaC1,8 mM Na2HP04, 1 mM NaH2P04, 1 mM EDTA, and 350 mglml digitonin. The 
lysates were then centrifuged at 12,000 x g for 1 minute in a Cyto-Tek centrifuge, and the 
supernatant was collected and added to an equal volume of 2x sample buffer. 1 ml of 2x 
sample buffer contains 125 mM Tris base (pH 6.8), 2% SDS, 100 mM DTT, 10% glycerol. 
The resulting protein samples were quantified using the same procedure described in the 
previous section and separated by 15% SDS-PAGE, and subjected to western blot analysis 
as described by the procedure in section 2.14. Anticytochrome c (mouse monoclonal; 
PharMingen) was the primary antibody used at a dilution of 1:500. 
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2.16 Statistical Analysis 
For analysis of apoptosis (morphology and Annexin V), cell viability, and colony 
forming ability, values represent the means h standard deviation for at least three separate 
experiments performed in triplicate. Analysis of synergism was performed according to 
Median Dose Effect analysis using Calcusyn and Prism software programs (Biosoft, 
Ferguson, MO). Statistical analysis was done using Prism Pad Software, version 3 
(Biosoft, Ferguson MO) using a student's t-test at an a priori significance level of p 5 0.05. 
Results and Data Analysis 
3.1 Co-administration of UCN-01 and Co-enzyme Reductase Inhibitors Induces a 
Dramatic Apoptotic Response. 
In the Figure 3.1, U937 and Jurkat cells were exposed to lovastatin and UCN-01 
individually over a course of 18 hours. Following treatment over 18 hours, 400 uL of cells 
were collected and treated to DiOC6 dye for membrane potential analysis. Apoptosis was 
determined by the amount of DiOC6 taken up by the cell. For consistently varying doses 
administered up to 150 nM of UCN-0 1, the degree of apoptosis shows a marked, but 
gradual increase compared to the control cells (p 5 0.05). However, when the cells were 
exposed to lovastatin (HMG CoenzymeA reductase inhibitor) combined with UCN-01 at 
lower doses there is a significant increase (p 5 0.05) in the amount of apoptosis to 70 % 
compared to cells exposed to UCN-01 alone. In Figure 3.2, there is a significant (p 5 0.05) 
increase in apoptosis compared to the control cells when treated with gradually increasing 
doses of lovastatin. However, cells treated with lovastatin combined with UCN-01 show a 
significant (p 5 0.05) increase compared to cells treated with lovastatin alone. As 
illustrated in Figure 3.3 for U937 (bottom left) and Jurkat cells (bottom right), combination 
indexes are lower than 1.0 indicating synergistic interactions when administering LV and 
UCN-01 at a constant ratio of 1000:5. The graphs below were created using Calcusyn 
software. 
Figure 3.1: Dose Response for U937 and Jurkat Cells (18 Hours) 
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Figure 3.2: Dose Response for U937 and Jurkat Cells (18 Hours) 
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Figure 3.3: Combination Index for Jurkat and U937 Cells 
Y 
(1 0'2 O'b Oh Ob 
Fract~onal Effect Fractional Effect 
3.2. UCN-01 Combined with Lovastatin Induces PARP Cleavage and Caspase 
Activation. 
The western blots in Figure 3.4 indicate that one possible mechanism by which 
Lovastatin and UCN-01 induce apoptosis in leukemia cells is via the intrinsic pathway as 
illustrated in the section I. Jurkat and U937 cells were treated with each condition as 
indicated for 18 hours, cells were collected and pelleted and subjected to western blot 
analysis as described in the materials and methods section. The data below demonstrates 
that UCN-01 combined with the stains tested induces caspase 3,8, and 9 and PARP 
cleavage. In these studies all three forms of statins were tested and varied slightly in their 
potency. Once each western blot was probed with the primary antibody, all western blots 
were washed in TBS-Tween 20 and re-probed with actin to ensure equal loading. To 
differentiate between apoptosis and necrosis, further testing was done via annexin V 
analysis (panel A) as indicated by the PI and annexin V stained cells in the upper and 
lower right quadrants, respectively. Compared to the control, there is a marked shift in the 
amount of cells to the upper and lower right quadrants stained with PI or annexin, 
indicating early and late apoptosis. 
Figure 3.4: Annexin and Western Blot Analysis 
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3.3 UCN-OlIHMG-CoA Reductase Inhibitors Induces G2M Abrogation and Changes 
Cell Morphology 
The DNA staining illustrated in Figure 3.5A was done in order assess changes in 
morphology and confirm apoptotic responses done during annexin staining. As mentioned 
previously, in the methods section, the above cells were lysed and DNA was extracted 
from the resulting supernatant then treated with sample buffer and separated via agarose 
gel electrophoresis. The gel was stained with ethidium bromide and viewed under cannon 
photomicroscopy. The graphs in Figure 3.5 By demonstate that there is a marked increase 
of cells in the G2M phase of the cell cycle when leukemia cells (U937) are exposed to 
UCN-01 or with HMG-CoerizymeA Yeductase inhibitors, individually. In addition, DNA 
analysis demonstrates dramatic apoptotic responses due to DNA damage in cells exposed 
to both reagents. 
Figure 3.5: DNA Analysis and Cell Cycle 
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3.4 UCN-01 and Lovastatin Induce Mitochondrid Membrane Damage and Induces 
XIAP and Caspase 3 Cleavage. 
In order to hrther assess the exact mechanism of apoptosis and determine cytosolic 
distribution, leukemia cells were assessed via cytochrome c analysis (data not shown). 
Cells overexpressing U937/CA-XIAP and U937/Empty vector cells were treated with 
lovastatin (20 uM)IIJCN-01 (100 nM) for 18 hours and annexin V analysis was performed 
on untreated cells and the combination of lovastatin and UCN-01. Figure 3.6 indicates the 
release of cytochrome C and AIF expression when exposed to both lovastatin and UCN- 
01. Compared with the XIAP/Empty vector cells, U937/CA- XtAP cells indicate a 
significant (p 5 0.05) resistance to apoptosis when exposed to UCN-Ol/LV (18 hours). 
Figure 3.6: Western Blots and Cytochrome C Analysis 
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3.5 Lovastatin Blocks MEK/ERK Pathway Activated by UCN-01 
In Figure 3.7, leukemia cells were subjected to western blot analysis. As indicated 
above, ERK is activated by UCN-0 1 documented by the strong expression of phospho- 
E M  when leukemia cells are exposed to UCN-0 1 alone and a marked increase in JNK 
phosphorylation when combined with HMG CoA reductase inhibitors. However, when 
lovastatin is administered (lane 3), p-ERK levels are dramatically decreased compared to 
the amount of p-ERK expressed in the presence of UCN-0 1 alone. UCN-0 1, slightly 
decreased p-cdc2 expression, whereas the combination of statinlUCN-0 1 dramatically 
down-regulated of p-cdc2 phosphorylation. Finally, western blots were performed on two 
RAS isoforms in order to assess the dominant isoform involved in RAS inhibition. 
According to the blot, fluctuations in HRAS expression indicate that the unprocessed or 
unmodified RAS (band 6) expression increases with the addition of lovastatin, simvastatin, 
and fluvastatin. When lovastatin is administered in combination with UCN-01 these effects 
are also present. 
Figure 3.7 PI3KlAKT ad RAS/RAF/MEK/ERK Pathway 
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3.6: Myeloma Cells Show Dramatic Apoptotic Response. 
The cell lines below for 8226lSensitive cells and MM.1R Cells were subjected to 
DiOC6 analysis to indicate the optimal synergistic response. Various cell lines were used 
in the myeloma study to observe consistent protein expression and apoptotic response. The 
8226lSensitive cell lines and MM.1R cell lines were treated with a corresponding control, 
single, and combination of reagents for 18 and 24 hours. Figure 3.8 demonstrates a 
significant (p 1 0.05) increase in apoptosis compared to the control cells when exposed to 
UCN-01 alone in 8226lSensitive and 1R cells. In addition, Figure 3.8 illustrates a marked 
(p 5 0.05) increase in apoptosis when cells are exposed to UCN-01 combined with 
lovastatin compared to cells treated with UCN-0 1 or lovastatin alone. Figure 3.9 
demonstrates a significant (p 5 0.05)-increase in apoptosis compared to the control cells 
when exposed to lovastatin individually in 8226lSensitive and 1R cells. In addition, Figure 
3.9 illustrates a marked (p 5 0.05) increase in apoptosis when cells are exposed to UCN-01 
combined with lovastatin compared to cells treated with UCN-01 or lovastatin alone. U266 
cells were exposed to a 24,36, and 48 hours in order to determine the optimal synergistic 
response (data not shown). It was determined that the optimal time for treatment was 18 
hours for MM. 1R and 8226 cell lines. The optimal synergistic response was achieved when 
15 uM of lovastatin and 100 nM of UCN-0 1 were administered to 8226lSensitive cells and 
MM. 1 R cells. However, U226 cell lines were slightly more resistant and an optimal 
synergistic response was demonstrated at 36 hours with 10uM of lovastatin and 100 nM of 
UCN-0 1 (data not shown). For simvastatin, the same analysis was conducted as discussed 
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above and the optimal response was achieved at a combination of doses of 20 uM of MK 
and 100 nM of UCN-01 (data not shown). 
Figure 3.8 Dose Response for MM.1R Cells and 8226 Cells (18 Hours) 
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Figure 3.9 Dose Response for MM.1R and 8226 Cells (18 Hours) 
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Figure 3.10: Combination Index for MM.1R and 8226 Cells (18 Hours) 
3.7 Mitochondria1 Dysfunction and PARP Cleavage. 
In Figure 3.1 1, the western blots demonstrate caspase 8 and caspase 9 cleavage 
consistently throughout the myeloma cell line indicating that the mechanism involved in 
the apoptotic response with UCN-0 llstatin combination causes mitochondria1 dysfunction 
and involves the intrinsic pathway. In addition, PARP cleavage and XIAP cleavage also 
indicate a similar molecular mechanism to that which occurs in leukemia cells. Annexin 
analysis confirms apoptotic responses illustrated in preliminary DiOC6 analysis. 
Figure 3.1 1 Mitochondria1 Dysfunction and Annexin V Analysis (8226 Cells) 
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3.8 Inhibition of HRAS in Multiple Myeloma. 
As demonstrated in Figure 3.12, inhibition of HRAS may be involved in the 
apoptotic response with multiple myeloma cells as seen consistently in leukemia cells. In 
Figure 3.12, 8226lSensitive cells indicated a very clear expression of the unprocessed 
HRAS when exposed to the UCN-Ollstatin combination of reagents. As a result, M h e r  
studies were done using U266lCA-HRAS cells in order to clearly assess that HRAS plays 
a predominate role in RAS inhibition in multiple myeloma. Figure 3.12 B demonstrates 
that U266lEmpty Vector cells conferred significant (p 5 0.05) sensitivity compared to 
U266lCA-HRAS cells exposed to UCN-01 and lovastatin. Other small GTP proteins were 
tested to determine consistencies in protein expression among leukemia and multiple 
myeloma cells including Rho B and RAPA. Figure 3.12 A strongly indicates that UCN- 
Olllovastatin inhibit RAS processing to a mechanism similar to that demonstrated by 
leukemia cells. 
Figure 3.12 RAS Expression in Multiple Myeloma (8226lSensitive) 
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Discussion & Conclusion 
4.1 Exposure of Leukemia Cells to Low Levels of UCN-01 and Lovastatin in 
Combination Results in Dramatic Apoptotic Response. 
In Figure 3.1 Jurkat and Leukemia cells exhibit minimal apoptotic responses when 
exposed to either lovastatin or UCN-01 individually. In accordance with these results, 
apoptosis varies from about 20% cell death to that of nearly 70% when exposed to the 
combination. Apoptosis was not only assessed by mitochondria1 membrane potential, but 
confirmed via Wright-Giemsa stain preparation and annexin V analysis. Mitochondrial 
dysfunction indicated by DiOC6 was confirmed by cytochrome C analysis. Not only is 
apoptosis dramatically increased, but cell proliferation is greatly reduced compared to the 
control as verified by clonegenecity assays (data not shown). Compared to several clones 
in the control group, the number of Jurkat and U937 clones decreased dramatically (nearly 
65 %) when treated by HMG CoA-reductase inhibitors1UCN-01 reagents. The degree of 
strength of each statin isoform varies slightly between the three forms tested with 
lovastatin having the greatest effect followed by simvastatin and fluvastatin. 
4.2 UCN-OlLovastatin Induces Apoptosis via the Mitochondrial Pathway 
Interestingly, abrogation of the G2 checkpoint appears to occur preferentially in 
cancer cells with defective p53 tumor suppressor function. UCN-01-induced G2 checkpoint 
abrogation has previously been shown to occur through a Cdc2-dependent pathway 
resulting in premature activation of this mitosis-promoting kinase in DNA-damaged cells. 
The molecular mechanism resulting in Cdc2 activation and G2 checkpoint abrogation by 
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UCN-01 are not known. Increased concentration of cytochrome C in the cytoplasm results 
from the nucleation of a multiprotein complex known as the apoptosome. The apoptosome 
is comprised of the Apaf-1 adapter protein, cytochrome C, dATP, and the aspartyl-directed 
protease caspase 9. Cytochrome C binds to Apaf- 1, and this facilitates an interaction 
between Apaf-1 and caspase 9. This interaction, in turn, activates the proteolytic activity of 
Caspase 9. 
4.3 Lovastatin Enhances UCN-01 Lethality Through Interruption of the 
RAS/RAFMEK/ERK Pathway in Leukemia and Multiple Myeloma Cells 
Because PI3WAKT represents a major downstream target of PUK, and has been 
linked, through both indirect and direct mechanisms, to a wide variety of antiapoptotic 
hct ions ,  it is tempting to say that lovastatin promotes the lethal effects of CDK inhibitors 
by blocking the activation of PUWAKT and one or more of its downstream targets, 
thereby lowering the threshold for mitochoiidrial damage and apoptosis. However, in the 
case of leukemia cells in this study it was found that while UCN-01 activated 
phosphorylation of ERK, activation of ERK was blocked when UCN-01 was combined 
with HMG CoenzyrneA reductase inhibitors and was primarily responsible for enhanced 
apoptosis. The pathways downstream of RAS including PI3WAKT and MEKtERK have 
repeatedly been shown to promote cell survival. This phenomenon has been confirmed by 
previous studies in which protein kinase C and Chkl inhibitor UCN-01 interacts in a highly 
synergistic manner with phannacologic reagents targeting the MEKIERK pathway in 
human leukemia and myeloma cells. Other agents, such as the Hsp90 antagonist 17-AAG, 
have also been shown to diminish UCN-01 -induced ERK activation and potentiate 
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apoptosis human leukemia cells, thereby mimicking the actions of pharmacologic MEK 
inhibitors, such as PD98059 and U0126 (25) and HMG-CoA reductase inhibitors. 
Interestingly, studies done with histone deacetylase inhibitors (HDACI) and alkyl- 
lysophospholipid perifosine were associated with an increase in reactive oxygen species 
(ROS) production and implicated oxidative damage in HDACIIperifosine lethality. 
Reactive oxygen species (ROS) have a major role in the mediation of cell damage. Several 
defense mechanisms attempt to minimize the production and the action of harmful 
oxidants. Such defense mechanisms include enzymes such as superoxide dismutase, 
catalase, and glutathione peroxidase, as well as natural lipophilic and hydrophilic 
antioxidants. Excessive ROS or inhibitiors of antioxidant pathways induce apoptosis. 
Ceramide belongs to the class of sphingolipids, cholesterol and free fatty acids. Increased 
levels of intracellular ceramides may either induce cell differentiation andlor apoptosis and 
reduced cell proliferation, initiating pro-apoptotic signaling. The relationship between the 
ceramide and ROS may vary with the cell type and inciting stimulus. For example, 
although ceramide generates ROSY increases in ROS formation can increase ceramide 
levels in certain cells (26). More importantly, enforced activation of PI3 WAKT or 
MEWERK blocked HDACLIperifosine-mediated ceramide generation (26). Previous 
studies have shown that ceramide and ROS can down-regulate PI3WAKT through a 
caspase-dependent process. Conversely, ceramide blocks 3-phosphoinositide binding to the 
pleckstrin homology domain of PI3WAKT. In addition, coadministration of HDACIs and 
perifosine failed to increase ceramide levels in cells expressing constitutively active 
PI3WAKT or MEWERK. Together, these findings show that inactivation of both 
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MEKIERK and PI3 WAKT is required for HDACIlperifosine-induced ceranlide production 
and subsequent apoptosis. Although the above study demonstrates apoptotic mechanisms 
involving other pathways, the similar phenomenon among these inhibitors is the ability to 
interrupt the MEWERK and PI3UAKT activity to induce subsequent apoptosis. 
4.4 Conclusions and Further Research 
The above study suggests that RAS plays a particularly important role in preventing 
apoptosis in leukemic cells experiencing CDK dysregulation. In addition, these and earlier 
studies focusing on interactions between UCN-01 and MEK112 inhibitors provide further 
evidence that leukemia cells are particularly sensitive when components of the cell cycle 
and survival signaling events are simultaneously disrupted. In several studies 
dysregulation of the PI3 WAKT pathway is associated with transformation, and there is 
extensive evidence that inhibitors of PI3UAKT can enhance the lethality of present 
chemotherapeutics. As a result, researchers have searched for clinically relevant agents that 
interrupt the PI3WAKT pathway and pathways that activate downstreams targets of 
PI3WAKT. Specifically, the present studies suggest that HMG- CoA reductase inhibitors, 
by blocking the PI3WAKT and MEWERK pathway may represent useful agents to 
enhance the anti-tumor efficacy of agents like UCN-01. There is abundant evidence that 
activation of the PI3UAKT pathway exerts antiapoptotic effects, although the 
mechanism(s) by which this phenomenon occurs is not entirely understood and may vary 
with cell type. Western blot analysis has indicated mitochondria1 dysfunction and 
sensitivity to statin/UCN-01 reagents; however, the exact apoptotic mechanism is not clear. 
Further studies are required to clarify the exact RAS isoform involved in PI3 WAKT 
regulation. 
Literature Cited 
1. Chai J., Du C., Wu J. W., Kyin S., Wang X., Shi Y. Structural and biochemical 
basis of apoptotic activation by Smac/DIABLO. Nature (Lond.), 406: 855-862, 
2000. 
2. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res. 
2003 Jan;9(1): 10-9. Review. 
3. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, 
Franklin RAY McCubrey JA. Involvement of PI3WAkt pathway in cell cycle 
progression, apoptosis, and neoplastic transformation: a target for cancer 
chemotherapy. Leukemia. 2003 Mar;17(3):590-603. Review. 
4. Chauhan D., Pandey P., Ogata A., Teoh G., Krett N., Halgren R., Rosen S., 
Kufe D., Kharbanda S., Anderson K. Cytochrome c-dependent and - 
independent induction of apoptosis in multiple myeloma cells. J. Biol. Chem., 
272: 29995-29997, 1997. 
5. Cheng EH, Wei MC, Weiler S, et al. BCL-2, BCL-X(L) sequester BH3 
domain-only molecules preventing BAX- and BAK-mediated mitochondrial 
apoptosis. Mol Cell. 2001 ;8: 705-7 1 1. 
6. Dai Y, Grant S. Cyclin-dependent kinase inhibitors. Cwrr Opin Pharrnacol. 
2003 Aug;3(4):362-70. Review. 
7. Dai Y, Rahmani M, Pei XY, Khanna P, Han SI, Mitchell C, Dent P, Grant S. 
Farnesyltransferase inhibitors interact synergistically with the Chkl inhibitor 
UCN-01 to induce apoptosis in human leukemia cells through interruption of 
both Akt and MEWERK pathways and activation of SEK11JNK.Blood. 2005 
Feb 15;105(4): 1706-16.2004 Oct 19. 
8. Dai Y, Yu C, Singh V, Tang L, Wang Z, McInistry R, Dent P, Grant S. 
Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) 
kinase/MAPK cascade interact synergistically with UCN-01 to induce 
mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res. 
2001 Jul 1;61(13):5106-15. 
9. Davies S. P., Reddy H., Caivano M., Cohen P. Specificity and mechanism of 
action of some commonly used protein kinase inhibitors. Biochem. J., 351: 95- 
105,2000. 
10. Decker RH, Dai Y, Grant S. The cyclin-dependent kinase inhibitor flavopiridol 
induces apoptosis in human leukemia cells (U937) through the mitochondria1 
rather than the receptor-mediated pathway. Cell Death Differ. 2001 
Ju1;8(7):715-24. 
11. Derijard B, Raingeaud J, Barrett T, et al. Independent human MAP-kinase 
signal transduction pathways defined by MEK and MKK isoforms. Science. 
1995;267: 682-685. 
12. Huang S, Shu L, Dilling MB, Easton J, Harwood FC, Ichijo H, and Houghton 
PJ (2003) Sustained activation of the JNK cascade and rapamycin-induced 
apoptosis are suppressed by p53/p21(Cipl). 11: 1491-1 501. 
13. Jia W, Yu C, Rahmani M, Krystal G, Sausville EA, Dent P, Grant S. 
Synergistic antileukemic interactions between 17-AAG and UCN-0 1 involve 
interruption of RAFIMEK-and AKT-related pathways. Blood. 2003 Sep 
1;102(5): 1824-32.2003 May 8. 
14. Johnstone RW, Ruefli AA, and Lowe SW (2002) Apoptosis: a link between 
cancer genetics and chemotherapy. Cell 108: 153-1 64. 
15. Hsu J, Shi Y, Krajewski S, et a1 The AKT kinase is activated in multiple 
myeloma tumor cells. Blood, 98: 2853-5,2001. 
16. Kawakami K, Futami H, Takahara J, Yamaguchi K. UCN-01, 7-hydroxyl- 
staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces 
the phosphorylation of the retinoblastoma susceptibility gene product in A549 
human lung cancer cell line. Biochem Biophys Res Commun. 1996;219:778- 
783. 
17. Kim K, Fisher MJ, Xu S-Q, and El-Deiry WS (2000) Molecular determinants of 
response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 6: 
335-346. 
18. King K. L., Cidlowski J. A. Cell cycle and apoptosis: common pathways to life 
and death. J. Cell. Biochem., 58: 175-1 80, 1995. 
19. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors 
flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins 
in B-cell chronic lymphocytic leukemia. Blood. 2000 Jul 15;96(2):393-7. 
20. Lam L, Cao Y. Statins and their roles in cancer. Timely Top Med Cardiovasc 
Dis. 2005 Sep 1;9:E23. 
21. Leppa S., Bohmann D. Diverse functions of JNK signaling and c-Jun in stress 
response and apoptosis. Oncogene, 18: 61 58-6162, 1999. 
22. Macdonald SG, Crews CM, Wu L, et al. Reconstitution of the RAF-1-MEK- 
ERK signal transduction pathway in vitro. Mol Cell Biol. 1993; 13: 661 5-6620. 
23. Milella M, Precupanu CM, Gregorj C, Ricciardi MR, Petrucci MT, Kornblau 
SM, Tafuri A, Andreeff M. Beyond single pathway inhibition: MEK inhibitors 
as a platform for the development of pharmacological combinations with 
synergistic anti-leukemic effects.Curr Pharm Des. 2005; 1 l(2 1):2779-95. 
Review. 
24. Petak I, Houghton JA. Shared pathways: death receptors and cytotoxic drugs in 
cancer therapy. Path01 Oncol Res. 2001;7(2):95-106. Review. 
25. Pumiglia K. M., Decker S. J. Cell cycle arrest mediated by the MEWmitogen- 
activated protein kinase pathway. Proc. Natl. Acad. Sci. USA, 94: 448-452, 
1997. 
26. Rahmani M, Yu C, Reese E, Ahmed W, Hirsch K, Dent P, and Grant S (2003) 
Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase 
inhibitor-mediated apoptosis through ~44142 MAP kinase inactivation and 
abrogation of p2 1 (CIP 1 /WAF 1) induction rather than AKT inhibition. 
Oncogene 22: 623 1-6242. 
27. Sausville EA, Arbuck SG, Messmann R, et al. Phase I trial of 72-hour 
continuous infusion UCN-01 in patients with refractory neoplasms. J Clin 
Oncol. 2001 ;19: 23 19-2333. 
28. Shao RG, Shimizu T, Pomrnier Y. 7-Hydroxystaurosporine (UCN-01) induces 
apoptosis in human colon carcinoma and leukemia cells independently of p53. 
Exp Cell Res. 1997 Aug 1;234(2):388-97. 
29. Shi Z, Azurna A, Sarnpath D, Li YX, Huang P, Plunkett W. Phase arrest by 
nucleosides analogues and abrogation of survival without cell cycle progression 
by hydroxystaurosporine.Cancer Res. 2001 Feb 1 ;61(3): 1065-72. 
30. Senderowicz AM. Inhibitors of cyclin-dependent kinase modulators for cancer 
therapy. Prog Drug Res. 2005;63: 183-206. 
31. Senderowicz AM. Development of cyclin-dependent kinase modulators as 
novel therapeutic approaches for hematological malignancies. Leukemia. 2001 
Jan; l5(1): 1-9. Review. 
32. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Ninmual A, Bar-Sagi D, Jones 
SN, Flavell RA, and Davis RJ (2000) Requirement of JNK for stress-induced 
activation of the cytochrome c-mediated death pathway. Science (Wash DC) 
288: 870-874. 
33. Verheij M., Bose R., Lin X. H., ~ a o  B., Jarvis W. D., Grant S., Birrer M. J., 
Szabo E., Zon L. I., Kyriakis J. M., Haimovitz-Friedman A., Fuks Z., Kolesnick 
R. Requirement for ceramide-initiated SAPKfJNK signaling in stress-induced 
apoptosis. Nature (Lond.), 380: 75-79, 1996. 
34. von Gise A, Lorenz P, Wellbrock C, et al. Apoptosis suppression by RAF-1 and 
MEKl requires MEK- and phosphatidylinositol 3-kinase-dependent signals. 
Mol Cell Biol. 2001 ;21: 2324-2336. 
35. Yarnauchi T, Keating MJ, Plunkett W. UCN-01 (7-hydroxystaurosporine) 
inhibits DNA repair and increases cytotoxicity in normal lymphocytes and 
chronic lymphocytic leukemia lymphocytes. Mol Cancer Ther. 2002 
Feb;1(4):287-94. 
36. Yang J., Liu X., Bhalla K., Kim C. N., Ibrado A. M., Cai J., Peng T. I., Jones D. 
P., Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from 
mitochondria blocked. Science (Wash. DC), 275: 1 129-1 132, 1997. 
37. Yu C, Wang S, Dent P, Grant S. Sequence-dependent potentiation of paclitaxel- 
mediated apoptosis in human leukemia cells by inhibitors of the mitogen- 
activated protein kinase kinaselmitogen-activated protein kinase pathway. Mol 
Pharmacol. 2001;60: 143-1 54. 
38. Wang Q, Worland PJ, Clark JL, Carlson BA, Sausville EA. Apoptosis in 7- 
hydroxystaurosporine-treated T lymphoblasts correlates with activation of 
cyclin-dependent kinases 1 and 2.Cell Growth Differ. 1995 Aug;6(8):927-36. 
Erratum in: Cell Growth Differ 1995 Oct;6(10): 1339. 
39. Widmann C, Gibson S, Johnson GL. Caspase-dependent cleavage of signaling 
proteins during apoptosis. A turn-off mechanism for anti-apoptotic signals. J 
Biol Chem. 1998;273 : 714 1-7147 
Payal Khanna 
Richmond, VA Educatim 0911998-0512002 Virginia Commonwealth University 
~ s o f x i i  
Major: Biomedical Engineering: Minor: Physics 
09R002-12RWS Vilginia Commonwealth University Richmond, VA 
mastePsofSclence 
Major B'omedml Engineering; Thesis: ApoptoDis using HMOCoA Reductas Inhibitors 
Work May 2WBPresent MCV HospitalsNCU 
- CladuateS(udsnt 
Richmond, VA 
Techniqueslbaimirg in Weftem Blotting, tramfection of cell lines, mainknance of leukemia and myeloma cell 
lines. flow cytwneby, immunoMng 
Involved a- studies of leuk&nii and Myeloma cell lines induding Jurkat and U937 dl lines when 
ex- to &us chemdheraph. 
Sept. 2001-May 2002 MCV HospitalsNCU 
SenbrDeslgnM-F-ht 
Richmond, VA 
Aim was to M g n  a bioreacbr h t  allows e l k  to seed onto a polymer scaffold and design an 
apparatuSheUlod to allow celk to proliferate and mechanicauy condwn e l k  to form a strong vessel. 
Tested the strength ofthe mse l  as a result of pressure and performed mechanical strengthening tests using 
MTS ofthe resulting artifiaal gRAFt 
August 2000-September 2002 PMUSA Research Park 
1 e l s s l s t a n t  
Richmond, VA 
Assisted researden and graduateiPhD students in the W of Nano-sized metallics. 
Weekly presentaSons to mrporafnn on research conduded. 
Filtmtkm research to reduce harmful mdtiluents in induml pollution such as carbon monoxkie. Included 
researching p r l i e o  of Nanopawes and working vdth a paltide sire analyzer and zeta potential. 
Composition analysb was done using a miuobalance, calcfimekic system and extended ex$erimenWn 
using various surlaces in a laboratory setting. 
-and WY. Rahmani M. m, Khanna P. &&I, Mitchell C. Dent P, Grant S., Blood. 
WlCLIUolg 'Farnetyltnnsfefenre inhiblton intonct syneraisticallv with the Chkl Inhibitor UCN-01 to induce . - 
apoptoais in  human leukemia cells through interruption of both Akt and MEKERK pathways and 
activation of SEKIIJNK." Feb. 2005. 
